|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ceftaroline fosamil]] |
| {{Ceftaroline}}
| |
| {{CMG}};{{AE}}{{AK}}
| |
| | |
| ==Overview==
| |
| Ceftaroline fosamil (INN) /sɛfˈtærɵliːn/, brand name Teflaro in the US and Zinforo in Europe, is an advanced-generation[1] cephalosporinantibiotic. It is active against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria. It retains the activity of later-generation cephalosporins having broad-spectrum activity against Gram-negative bacteria. It is currently being investigated for community-acquired pneumonia[2] and complicated skin and skin structure infection.
| |
| | |
| ==Category==
| |
| [[Cephalosporins]], third generation.
| |
| | |
| ==US Brand Names==
| |
| | |
| TEFLARO<sup>®</sup>
| |
| | |
| | |
| ==FDA Package Insert==
| |
| '''[[Ceftaroline description|Description]]'''
| |
| '''| [[Ceftaroline clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Ceftaroline microbiology|Microbiology]]'''
| |
| '''| [[Ceftaroline indications and usage|Indications and Usage]]'''
| |
| '''| [[Ceftaroline contraindications|Contraindications]]'''
| |
| '''| [[Ceftaroline warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Ceftaroline adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Ceftaroline overdosage|Overdosage]]'''
| |
| '''| [[Ceftaroline dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Ceftaroline clinical studies|Clinical Studies]]'''
| |
| '''| [[Ceftaroline how supplied|How Supplied]]'''
| |
| '''| [[Ceftaroline labels and packages|Labels and Packages]]'''
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001lbl.pdf
| |
| [[Category:Antibiotics]]
| |
| [[Category:Wikinfect]]
| |